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Background: This study evaluates whether the difference in Toronto Alexithymia Scale-20 item (TAS-20) between patients with major
depression (MD), panic disorder (PD), eating disorders (ED), and substance use disorders (SUD) and healthy controls persisted after
controlling for the severity of anxiety and depression.
Methods: Thirty-eight patients with MD, 58 with PD, 52 with ED, and 30 with SUD and 78 healthy controls (C) completed the TAS-20, the
Hamilton Rating Scale for Anxiety (Ham-A), the Hamilton Rating Scale for Depression (Ham-D).
Results: The differences in TAS-20 scores observed between patient groups, regardless of the type of their disorders, and controls
disappeared after controlling for the effect of anxiety and depression severity. In contrast, the differences in severity of anxiety and depression
between patients and controls were still present, after excluding the effect of alexithymic levels.
Conclusions: Our data suggest that alexithymic levels, as measured by the TAS-20, are modulated by the severity of symptoms, supporting
the view that alexithymia can represent a state phenomenon in patients with MD, PD, ED and SUD, because the TAS-20 seems overly
sensitive to a general distress syndrome, and it is more likely to measure negative affects rather than alexithymia itself.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Alexithymia is a multidimensional construct characterized
by an impoverished fantasy life, difficulty in expressing or
naming feelings, difficulty distinguishing between bodily
sensations and feelings, and a preoccupation with external
events [1]. The TAS-20 is the most widely used and studied
self-report measure of alexithymia. Factor analysis has
supported three-factor solutions for this scale: the factors
represent (1) difficulty identifying feelings (DIF), (2) difficulty
communicating and describing feelings (DDF), and (3)
external-oriented thinking (EOT). Items representing impo-Conflict of interests: No authors received funding for the research and
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http://dx.doi.org/10.1016/j.comppsych.2013.12.008verished fantasy or reduced daydreaming were dropped from
the TAS-20 based on the factor analyses solutions.
Alexithymia, reflecting a disordered affect regulation, is
thought to increase vulnerability to psychological illness,
especially in conflict-afflicted psychosocial situations.
Therefore, people with alexithymic personality are supposed
to be at risk for developing mental disorders such as major
depression [1], panic disorder [2], eating disorders [3] and
substance use disorders [4].
Concerning major depression (MD) the rate of alexithy-
mia ranges between 45% and 46% during the acute phase of
illness [5–11]. A similar rate of alexithymia (29%–44%) was
found in the active phase of panic disorder (PD) [2,12], and
even higher rates (23%–77%) were observed in patients with
eating disorders (ED) (anorexia nervosa, bulimia nervosa
and binge eating disorder) [13–16] and in patients with
substance use disorders (SUD) (i.e., between 45% and 67%
of patients with alcohol use disorders) [17].
However, the evaluation of alexithymia with the TAS-20
can be limited by the fact that alexithymia cannot be validly
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alexithymia, by definition, should not be able to report their
psychological state.
Further, when alexithymia was assessed with the TAS-20,
significant relationships have been found with depression
and anxiety not only in the general population [18,19], but
also in clinical samples. In the general population, depressive
symptoms explained almost 36% of the variance in
alexithymic features [18] or were significantly correlated
with all alexithymic dimensions (DIF: r = 0.52; DDF: r =
0.42; EOT: r = 0.20) [19].
In clinical samples, some studies observed a decrease in
the TAS-20 scores when depressive symptoms improved in
MD [5–11,20] or when anxiety symptoms decreased in PD
[2]. Moreover, an overlap between TAS-20 (particularly the
DIF dimension) and anxiety was found in a factor analysis
study in patients with anxiety or depressive disorders [25],
and an association between alexithymia and severity of
depression and anxiety was also found in SUD [21–24] and
in ED [3,14].
Altogether the aforementioned findings raise the question
whether the TAS-20 measures negative affects rather than
alexithymia itself in mental disorder. Hoffart [26] and
Lumley [27] suggest a method to answer this question: if the
TAS-20 identifies alexithymic traits the differences between
patients and healthy controls should persist after controlling
for anxiety and depression. To our knowledge, however, no
study investigating alexithymia in mental disorders with the
TAS-20 applied this method.
Therefore the present study aimed to clarify whether the
differences in TAS-20 scores among patients with MD,
PD, ED and SUD and healthy controls remained after
controlling for the effect of the severity of anxious and
depressive symptoms.2. Materials and methods
2.1. Sample
Patients were recruited from all patients who consec-
utively sought treatment at the outpatient service of the
Psychiatry Clinic of the University of Parma-Italy from
January to December 2011, after receiving a diagnosis of
MD, PD, ED or SUD. The local ethics committee
approved the study protocol and the study was conducted
according to the Helsinki Declaration. All patients
provided informed consent.
Exclusion criteria for study participation were the
presence of schizophrenia or other psychotic disorders,
organic mental disorders, severe suicidal risk, a history of
neurological or medical disorder, a BMI lower than 16 for
ED patients and abstinence from substances for less than
2 months for SUD subjects.
The control group comprised age- and sex-matched healthy
subjects, recruited from university and hospital employers.2.2. Assessment
After giving informed consent, all subjects were adminis-
tered the Structured Clinical Interview for DSM-IV Disorders
[28], theHamiltonRating Scale for Anxiety (Ham-A) [29] and
for Depression (Ham-D) [30], the 20 item-Toronto Alexithy-
mia Scale (TAS-20) [31] and a semi-structured interview
assessing clinical and anamnestic information.
A resident in psychiatry (P.O.) was specifically trained to
administer the SCID. The training consisted in the
administration of the SCID to 10 patients affected by
major depression, dysthymia, panic disorder, generalized
anxiety disorder, anorexia nervosa, bulimia nervosa, binge
eating disorder, cocaine or heroin dependence. The in-
terviews were audiotaped and reviewed by a senior
psychiatrist (C.M.). A satisfactory diagnostic reliability
(k = 0.79) was obtained during the training.
2.3. Statistical analysis
The internal consistency for the TAS-20 was calculated in
each diagnostic group. The Cronbach α was .78 in the MD
group, .87 in the PD group, .83 in the ED group, .81 in the
UD group and .80 in the control group. The values obtained
in each group demonstrated that patients were able to
understand the questions and to respond to the items in an
appropriate and consistent way. Differences among the
diagnostic groups were evaluated using χ2 for categorical
variables and one-way ANOVA with Bonferroni post hoc
analysis for continuous variables, as appropriate.
We used Pearson correlation to evaluate how alexithymia
was related to age and education.
We used analysis of covariance (ANCOVA) to evaluate the
between-groups differences on TAS-20 scores after adjusting
for age and education, which were found to be significantly
different among diagnostic groups. Moreover, we then used
analysis of covariance (ANCOVA) to evaluate the between-
groups differences on the following: (1) TAS-20 scores, after
controlling for age, gender, education and severity of anxious
and depressive symptoms (Ham-A and Ham-D scores), and
(2) Ham-A and Ham-D scores, after controlling for the effect
TAS-20 total, DIF, DDF, and EOT scores.
Finally, linear regression analysis was used to evaluate
the relationship between TAS-20 total, DIF, DDF and EOT
scores (dependent variables) and age, gender (0 = male; 1 =
female), years of education, Ham-A and Ham-D scores
(independent variables) in the whole sample, in order to
establish whether alexithymia levels were associated with
the severity of concurrent anxious and depressive symptoms.3. Results
3.1. Sample
A total of 178 patients and 78 healthy controls (C)
participated in this study. Within the clinical group, 38
patients were affected by MD, 58 by PD, 52 by ED (anorexia
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disorder n = 14) and 30 by SUD (cocaine dependence n =
10; heroin dependence n = 11; multiple substances depen-
dence n = 9). Table 1 shows the socio-demographic features
of both the patient and the control groups.
3.2. TAS-20 scores
TAS-20 total score was higher in MD, PD and ED patients
than in C, while the difference between SUD and C did not
reach statistical significance (Table 2). Patients with MD
showed the highest levels in all three subscales of TAS-20,
whereas ED reported higher scores than C only for DIF and
DDF, PD only for DIF dimension, and SUD only for DDF
dimension. All these differences persisted after controlling for
age and education (ANCOVA, TAS-20 total score: F = 16.8;
p b .001; DIF: F = 22.4; p b .001; DDF: F = 7.6; p b .001;
EOT: F = 5.5; p b .001), which significantly differed among
diagnostic groups, although only age correlated with the TAS-
20 scores (b = .14; p = .02). Among groups, all the above-
mentioned differences in TAS-20 scores disappeared after
controlling for the effect of severity of anxious and depressive
symptoms (Table 2).
3.3. Severity of anxious symptoms
Ham-A scores were significantly higher in patients than in
C. Among patients, the most anxious were those with MD
and the lowest those with SUD, with PD and ED lying in the
middle position (Table 2). The significant differences among
groups were still present after controlling for the effect of
age, gender, years of education DIF, DDF, and EOT scores
(Table 2).
3.4. Severity of depressive symptoms
The Ham-D scores were significantly higher in MD
patients than in PD, ED, SUD patients or in C. Moreover,
PD, ED, SD patients were more depressed than C (Table 2).Table 1
Socio-demographic and psychopathological characteristics of patients with major
dependence (SD) and healthy controls (C).
MD (n = 38) PD (n = 58) ED (n
Gender (female), n (%) 19 (50.0) 40 (69.0) 48 (92.
Age (years) 51.3 ± 11.7 36.3 ± 10.7 43.5 ±
Education (years) 9.9 ± 4.4 10.3 ± 3.5 10.3 ±
Family status, n (%)
Never married 9 (23.7) 19 (32.8) 12 (23.
Married 20 (52.6) 30 (51.7) 34 (65.
Separated/divorced 8 (21.1) 7 (12.1) 4 (7.7)
Widowed 1 (2.6) 2 (3.4) 2 (3.8)
Occupation, n (%)
Unemployed 5 (13.2) 5 (8.6) 4 (7.7)
Student – 9 (15.5) 3 (5.8)
Housewife 7 (18.4) 6 (10.3) 3 (5.8)
Employed 19 (50.0) 38 (65.5) 38 (73.
Retired 7 (18.4) – 4 (7.7)
Alexithymia, n (%)
TAS-20 score N60 17 (44.7) 16 (27.6) 17 (32.The significant differences among groups were still present
after controlling for the effect of age, gender, years of
education, DIF DDF, and EOT TAS-20 scores (Table 2).
3.5. Relationship between TAS-20 scores and anxiety
or depression
In the total sample, linear regression analyses showed
that TAS-20 scores were predicted by Ham-A scores (β =
.28; t = 3.0; p = .002) and Ham-D scores (β = .23; t = 2.5;
p = .01); DIF scores were predicted by Ham-A scores
(β = .47; t = 5.3; p b .001) and by female gender (β = .15;
t = 2.7; p = .006); DDF and EOT scores were both predicted
by Ham-D scores (β = .23; t = 2.2; p = .02; and β = .21;
t = 2.1; p = .03, respectively) and age (β = .17; t = 2.7;
p = .007).4. Discussion
This study evaluated whether patients with psychiatric
disorders (MD, PD, ED, SUD) show higher TAS-20 scores
than healthy controls even when controlling for the potential
confounding effect of anxious and depressive symptoms.
The results indicate that all patient groups, regardless of
their specific disorder, reported higher TAS-20 scores than
healthy C, although the difference between SUD patients and
C did not reach a statistical significance.
This finding confirms the results of previous studies that
assessed alexithymia with the TAS-20 in MD [5–11,32], PD
[2,12], ED [13–16] and SUD [17,23,24]. However, the
differences on TAS-20 total score observed among the
diagnostic groups disappeared after controlling for the effect
of anxious and depressive symptoms. This finding suggests
that the severity of anxious and depressive symptomatology
could account for the increased TAS-20 scores observed in
patients with different mental disorders: when the differences
in symptoms severity were controlled for, all patient groups,depression (MD), panic disorder (PD), eating disorder (ED), and substance
= 52) SD (n = 30) C (n = 78)
3) 6 (20.0) 63 (80.8) χ2 = 58.0; p b .001
12.5 33.2 ± 9.6 41.2 ± 11.8 F = 14.0; p b .001
3.5 8.7 ± 3.0 8.4 ± 3.6 F = 3.6; p = .007
χ2 = 58.5; p b .001
1) 27 (90.0) 22 (28.2)
4) 2 (6.7) 48 (61.5)
1 (3.3) 3 (3.8)
– 5 (6.4)
χ2 = 64.1; p b .001
13 (43.3) 5 (6.4)
1 (3.3) 7 (9.0)
1 (3.3) 18 (23.1)
1) 15 (50.0) 43 (55.1)
– 5 (6.4)
7) 5 (16.7) 4 (5.1) χ2 = 28.2; p b .001
Table 2
Severity of depressive–anxious symptoms and levels of alexithymia in patients with major depression (MD, panic disorder (PD), eating disorders (ED),
substance use disorders (SUD and in healthy controls (C).
MD (n = 38) PD (n = 58) ED (n = 52) SUD (n = 30) C (n = 78) One-way ANOVA (df = 4,251)
Ham-A 25.1 ± 8.1 20.1 ± 7.0 16.5 ± 4.7 11.3 ± 5.1 1.9 ± 2.3 F = 153.9; p b .001a
Ham-D 24.7 ± 6.6 13.7 ± 6.1 11.5 ± 4.7 13.1 ± 5.2 1.9 ± 2.0 F = 147.7; p b .001b
TAS-20
DIF 21.5 ± 7.2 20.9 ± 6.4 20.2 ± 6.7 16.1 ± 6.2 13.0 ± 4.8 F = 21.6; p b .001c
DDF 16.0 ± 4.8 12.6 ± 4.4 13.7 ± 5.5 14.3 ± 4.0 11.0 ± 4.6 F = 7.9; p b .001d
EOT 21.3 ± 3.0 18.7 ± 6.3 18.7 ± 6.3 17.7 ± 4.4 16.0 ± 5.9 F = 5.9; p b .001e
Total 58.9 ± 12.1 52.2 ± 14.4 53.0 ± 14.4 47.4 ± 11.4 40.1 ± 11.5 F = 16.9; p b .001f
Means adjusted for the effects of covariates ANCOVA
(df = 10,256)
Covariates: age, gender, education, DIF, DCF and EOT scores
Ham-A 24.7 ± 5.5 19.2 ± 5.3 15.7 ± 5.0 11.9 ± 5.4 3.0 ± 5.2 F = 88.4; p b .001a
Ham-D 23.8 ± 4.9 13.4 ± 4.5 11.0 ± 4.3 13.9 ± 4.9 2.6 ± 5.2 F = 90.6; p b .001b
Covariates: age, gender, education, Ham-A and Ham-D scores ANCOVA (df = 9,256)
TAS-20
DIF 17.8 ± 9.2 19.2 ± 6.0 19.2 ± 5.7 17.1 ± 6.5 16.3 ± 9.7 F = 1.4; p = .21
DDF 14.9 ± 7.3 12.0 ± 5.3 13.5 ± 5.0 14.1 ± 5.4 12.1 ± 7.9 F = 1.9; p = .10
EOT 18.5 ± 8.6 19.0 ± 6.9 19.0 ± 5.7 17.1 ± 6.0 17.3 ± 8.8 F = 0.6; p = .60
Total 51.3 ± 19.7 50.2 ± 14.4 52.1 ± 12.9 47.8 ± 14.2 45.7 ± 21.1 F = 1.0; p = .38
DIF, difficulty identifying feelings; DDF, difficulty communicating and describing feelings; EOT, external oriented thinking.
Bonferroni post hoc analysis.
a D N PD N ED N SD N C.
b D N PD, ED, SD N C.
c D, PD, ED N SD, C.
d D N PD, C; ED, SD N C.
e D N C.
f D N SD, C; PD, ED N C.
975C. Marchesi et al. / Comprehensive Psychiatry 55 (2014) 972–978regardless of their disorder, showed TAS-20 total scores
comparable to those reported by healthy controls.
At the same time, our results do not support the notion
that TAS-20 scores increase the risk for anxiety and
depression as suggested by some authors [33,34]. In order
to test this hypothesis, we also evaluated whether the
observed difference between patients and controls in
anxious and depressive psychopathology disappeared after
controlling for the effect of TAS-20 scores. Results showed
that this was not the case in our sample, suggesting that
TAS-20 levels do not influence the severity of anxious and
depressive symptoms.
Furthermore, the patient groups scored differently on the
three alexithymic dimensions.
Specifically, MD patients reported higher DIF, DDF and
EOT than controls, whereas ED patients showed an increase
only in DIF and DDF. PD patients were higher than controls
only on DIF, and SUD only on DDF. However, all these
observed differences among groups disappeared after
excluding the effect of symptoms severity, suggesting that
psychopathology severity was responsible for the increased
levels of the alexithymic dimensions. Thus, the different
patterns of alexithymia reported by diverse diagnostic groups
could be explained by the different effects of anxious and
depressive symptoms on the three alexithymic dimensions.In fact, in this study the severity of anxiety directly predicted
DIF scores (β = .47; p b .001), whereas the severity of
depression predicted DDF (β = .21; p = .03) and EOT
scores. Accordingly, the highest DIF, DDF, EOT scores
were found in MD patients, who also reported the highest
severity of anxious and depressive symptoms, while PD
patients, who were more anxious than depressed, were
higher than controls only on the DIF dimension, and SUD
patients, who were more depressed than anxious, were
higher than controls only with respect to DDF scores. Taken
together, these findings support the hypothesis of a specific
relationship between some anxiety and depressive symptoms
and definite alexithymic dimensions. Indeed, previous
studies [23,35,36] reported an association between psychic
anxiety and DIF dimension. Further, DDF elevation has been
associated with suicide ideation in depressed patients [37] as
well as with depersonalization/derealization in PD patients
[30] whereas the EOT dimension has been positively related
to psychomotor retardation in major depressed patients [38].
The results of this study have the potential to contribute to
the ongoing and long-lasting debate concerning the stability
of alexithymia among mental disorders. Several influential
authors [1,9,11,39] suggest that alexithymia is a personality
trait that, as such, is characterized by a relative stability: while
alexithymic levels can increase and decrease depending on
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among individuals remain stable over time. This hypothesis
implies that the basic personality conditions, which constitute
a liability toward a mental disorder, are accentuated by the
state of illness and return to the pre-existing conditions after
remission, as suggested by Hoffart [26]. According to this
trait–state hypothesis [26] a basic personality condition
constitutes a predispositional factor to the disorder whether
“the observed personality differences between diagnostic
groups will persist after symptom severity has been
controlled for.” With respect to alexithymia, this means that
if alexithymia was a personality trait in a mental disorder the
difference in TAS-20 scores observed between patients and
healthy controls should still hold true after excluding the
effect of illness symptoms. For instance, Lumley [27]
suggested to test the uniqueness of the TAS in the relationship
with depression by statistically controlling the other construct
and examining the residual relationship of the TAS with the
criterion. In the present study, the differences in TAS-20
scores among patients and between patients and healthy
controls disappeared, after controlling for the effect of the
severity of anxious and depressive symptoms. Therefore, our
findings do not support the hypothesis that alexithymia
behaves as a stable personality trait among patients with
psychiatric disorders; on the contrary, these data indicate that
alexithymia, as assessed by the TAS-20, is a state
phenomenon, because its levels appear to be modulated by
the severity of symptoms (and not vice versa). This confirms
our previous findings that amongwomen who developedMD
[20] or PD [40] alexithymia levels were in the normal range
prior to illness onset, but increased steadily during the acute
phase of the disorder.
There are at least two alternative explanations for the
observed relationship between alexithymia and anxiety and
depression. Alexithymia may be a temporary response to
stress represented by an illness episode; in this view
“secondary alexithymia” can represent a defense or a
strategy to cope with distress (emotional pain, aversive
memories and physiological arousal) associated with a
mental disorder [25]. In the second view, the relationship
between alexithymia and depression may represent an
artifact of the method and measures used [27], since,
particularly, the TAS-20 dimensions DIF and DDF are
associated with different measures of negative affects
[2,3,14,16,18,20,25,27,39,41–45]. Therefore individuals
with negative emotional states (i.e. anxiety and depression)
might score high on these TAS-20 dimensions.
The present study supports this latter view, since also in
mental disorders such as ED and SUD, which are frequently
associated with anxiety and depression, the higher levels of
TAS-20 scores disappeared when the effect of anxiety and
depression was excluded. This should have not occurred if
alexithymia was a personality trait predisposing people to
ED or SUD, as hypothesized by previous studies [46–48].
Thus, our study confirms the shortcomings with respect to
validity and reliability of TAS-20 in the assessment ofalexithymia in clinical samples [49,50]: alexithymia, as
assessed by the TAS-20, can be more a measure of negative
affect rather than a measure of deficit in the cognitive
processing of emotions across different mental disorders.
This seems particularly true for the DIF and DDF
dimensions, since DIF capture anxiety symptoms and DDF
is sensible to depressive symptoms. According to this view,
the proposed existence of an alexithymic depression [51],
characterized by high DIF and DDF levels, may be
questioned, since in the study of Vanheule et al. [51], even
though the alexithymic patients showed the most severe
depressive symptoms, the TAS-20 differences between
strongly and moderately alexithymic patients were not
adjusted the for the severity of anxious and depressive
symptoms. Similarly, also the conclusion of a recent study
can be questioned [52]. In the study of Leweke et al. [52], the
increased prevalence of alexithymic subjects in mental
disorders, especially in depressive disorders, let the authors
to conclude that alexithymia may be associated with a higher
vulnerability to mental illness, even though they did not
control if the high prevalence of alexithimic subject persisted
in mental disorders after adjusting for the severity of anxious
and depressive symptoms. Therefore, no conclusion about
the causal relationship between alexithymia and mental
disorders can be drawn from these two studies [51,52], since
the effect of negative affects on the TAS-20 scores was not
controlled for.5. Conclusion
The present study supports the hypothesis that the TAS-
20, the most widely used self-administered scale assessing
alexithymia, is overly sensitive to a general distress
syndrome, and therefore it is more likely to measure negative
affects (distress, nervousness, fear, anger, guilt, sadness,
scornfulness) rather than alexithymia itself. Future studies
investigating alexithymia among psychiatric populations
should control for the severity of anxiety and depression
before arguing that alexithymia is a personality trait
predisposing to mental disorders. Finally, the findings of
the present study, based only on a self-reported measure of
alexithymia, need to be confirmed using observer ratings
(e.g., Toronto Structured Interview for Alexithymia) or
objective performance-based tasks such as the Levels of
Emotional Awareness Scale.
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